AstraZeneca (($AZN)) has held its Q2 earnings call. Read on for the main highlights of the call. AstraZeneca’s recent earnings call showcased a ...

AstraZeneca has received a positive recommendation from NICE for the use of Imfinzi (durvalumab) with Imjudo (tremelimumab) ...

AstraZeneca (LSE:AZN) recently reported robust earnings results, with significant year-over-year increases in sales, revenue, ...

The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the use of ...

AstraZeneca’s Imfinzi (durvalumab) has been granted priority review by the US Food and Drug Administration (FDA) to treat ...

Cambridge: AstraZeneca has announced that the company's supplemental Biologics License Application (sBLA) for Imfinzi ...

AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with resectable, ...

AstraZeneca posted $14.46 billion in Q2 revenue, reaffirming its 2025 outlook as the FDA advances Imfinzi in gastric cancer.

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

The regulatory actions were based on results from the Phase III MATTERHORN trial (NCT04592913), which showed that a ...

AstraZeneca beat second-quarter profit forecasts on robust sales of cancer, heart and kidney disease drugs and strong demand ...

AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI (durvalumab) has been accepted and granted ...